A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

This study is testing a new immune system-modulating drug called SAR445877 in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has stopped responding to standard treatments. The goal is to see if the drug can help slow or reverse disease progression. **You may be eligible if...** - You are 18 or older - You have confirmed advanced or metastatic non-small cell lung cancer - Your cancer has progressed despite all available standard treatments, or you cannot tolerate those treatments - You have previously received an immune checkpoint inhibitor (such as a PD-1 or PD-L1 blocking drug) - You are in adequate health to participate and can give informed consent **You may NOT be eligible if...** - You have not had prior immunotherapy treatment - You have other serious health conditions that would make this experimental treatment unsafe - You are under 18 years old Talk to your doctor to see if this trial is right for you.